Jiangsu Hengrui Medicine
600276.SS
#439
Rank
A$78.22 B
Marketcap
A$11.79
Share price
-1.46%
Change (1 day)
21.25%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2025 (TTM): A$0.19

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is A$0.18. In 2024 the company made an earnings per share (EPS) of A$0.20 an increase over its 2023 EPS that were of A$0.14.

EPS history for Jiangsu Hengrui Medicine from 2000 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$0.19-1.76%
2024A$0.2042.43%
2023A$0.148.77%
2022A$0.13-20.62%
2021A$0.16-26.59%
2020A$0.2227.24%
2019A$0.1728.41%
2018A$0.1320.04%
2017A$0.1131.21%
2016A$0.0841611.46%
2015A$0.0755136.27%
2014A$0.0554119.77%
2013A$0.0462618.05%
2012A$0.0391923.9%
2011A$0.0316326.9%
2010A$0.0249212.37%
2009A$0.0221856.6%
2008A$0.014169.18%
2007A$0.01297114.48%
2006A$0.00604964.83%
2005A$0.00367035.55%
2004A$0.00270729.73%
2003A$0.00208719.86%
2002A$0.001741-2.71%
2001A$0.0017901.02%
2000A$0.001772